Wednesday, October 8, 2025

Latest

MediPharm Labs Report sees Quarterly Revenue Drop 25%

This morning MediPharm Labs (TSX: LABS) released their fourth quarter results for the year ended December 31, 2019. The quarter saw revenues decline approximately 25.4% from the previous quarter with a 73.6% decline in Adjusted EBITDA over the same period.

The previously beloved cannabis market darling saw a decline in pretty much everything on a quarterly basis:

Q4 2019Q3 2019% Change
Cash $  38,627  $   42,116 -8.3%
Inventory $  51,486  $   54,086 -4.8%
Receivables $  27,540  $   40,756 -32.4%
Accounts Payable $  20,946  $   41,704 -49.8%
Revenue $  32,444  $   43,486 -25.4%
Gross Profit $    9,987  $   14,754 -32.3%
Net Income (pre Tax) $  (2,401) $      5,395 -144.5%
Adjusted EBITDA $    2,661  $   10,066 -73.6%
Operating Cash Flow $  14,100  $   17,069 -17.4%
Investing Cash Flow $  (2,182) $ (10,799)-79.8%

The company cited oversupply of bulk extract, reduction in selling price, lower volumes, slower rollout of cannabis 2.0, slower rollout of retail and lastly a slower rollout of bigger companies entering the space.


The Company reported that the Canadian cannabis sector experienced significant challenges in the fourth quarter that resulted in an oversupply of bulk extract in the market and subsequent reduction in selling price and lower volumes. These factors included: a slower than anticipated expansion of retail channels in Canada, slower licensing of new and specialized cannabis 2.0 businesses, lower than expected conversion of bulk extract inventory into finished goods by vertically integrated players and slower than expected entry to the market by larger consumer packaged goods and pharmaceutical companies.


The company informed shareholders the manufacturing facility was exempted from the recent provincial mandated workplace closures as an essential service. But the company sees some issues with the supply chain potentially breaking down.

At the time of publishing MedipPharm Labs is down 14.65% to $1.69.


Information for this briefing was found via Sedar and MediPharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Fortune Bay: The Potential Billion Dollar Project

Japan Gold Enters New Chapter as Barrick Alliance Concludes – John Proust

Barrick Mining’s “Company Defining [Gold] Discovery”

Recommended

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Related News

Is 2020 The Year Cannabis Extractors Come Down With The Cronos Virus?

Our sharp-eyed editor Jay pointed out last week that cannabis cultivator Cronos Group Inc. (TSX:...

Sunday, March 15, 2020, 01:23:04 PM

Cronos Group Subject Of SEC Inquiry

This evening, MarketWatch reporter Max Cherney broke the story that Cronos Group (TSX: CRON) (NASDAQ:...

Thursday, March 19, 2020, 09:59:02 PM

MediPharm Labs, Vivo Cannabis Slump After Announcing All-Stock Deal

MediPharm Labs (TSX: LABS) announced on Thursday an all-equity deal to acquire VIVO Cannabis (TSX:...

Sunday, December 25, 2022, 01:35:00 PM

Medipharm Labs Announces White Label Agreement, Provides No Details

Medipharm Labs (TSX: LABS) has entered into its second white label supply agreement with its...

Monday, May 4, 2020, 08:24:41 AM

Medipharm Labs Receives Price Target Reduction From Canaccord To $1.75

Yesterday, On November 16th, Medipharm Labs (TSX: LABS) reported their third quarter financial results. Reported...

Tuesday, November 17, 2020, 03:37:00 PM